fraud | GenomeWeb

fraud

Give It Back

A major funding agency in China is cracking down on peer-review scams, ScienceInsider reports.

Experts believe that data in the single-molecule sequencing study published two years ago in Nature Nanotechnology was computer-generated.

The preliminary approval is the penultimate step to bringing to a close a class action lawsuit accusing Celera of making false and misleading statements about its finances.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Investors are suing China Medical Technologies alleging the firm engaged in actions that artificially inflated its stock in violation of US securities law.

Signal filed its suit against Med BioGene earlier this month alleging a breach of agreement, violation of a confidentiality agreement, and misuse of proprietary information, among other charges.

In a document filed with the SEC, Sequenom said that Elizabeth Dragon has pled guilty to charges of making false statements about the company's prenatal test for Down syndrome and will be sentenced on Aug. 30.

Transgenomic has claimed in a suit that Power3 has wrongly terminated a licensing deal between the firms, while engaging in fraud and slander.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.